Research Analysts Set Expectations for IRWD Q2 Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Analysts at Zacks Research lifted their Q2 2026 earnings per share (EPS) estimates for Ironwood Pharmaceuticals in a research note issued to investors on Monday, December 1st. Zacks Research analyst Team now expects that the biotechnology company will earn $0.09 per share for the quarter, up from their prior forecast of $0.08. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals’ Q4 2026 earnings at $0.16 EPS and FY2026 earnings at $0.39 EPS.

A number of other research analysts have also recently weighed in on IRWD. Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 9th. Wells Fargo & Company boosted their price objective on Ironwood Pharmaceuticals from $1.00 to $3.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 11th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a research note on Monday. One analyst has rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Ironwood Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $5.34.

Ironwood Pharmaceuticals Price Performance

IRWD opened at $3.73 on Thursday. The company has a 50 day simple moving average of $2.21 and a two-hundred day simple moving average of $1.35. The firm has a market cap of $606.79 million, a P/E ratio of 23.31 and a beta of 0.18. Ironwood Pharmaceuticals has a 1-year low of $0.53 and a 1-year high of $5.13.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Monday, November 10th. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.15. Ironwood Pharmaceuticals had a net margin of 8.70% and a negative return on equity of 15.17%. The company had revenue of $122.06 million during the quarter, compared to analyst estimates of $74.22 million.

Institutional Trading of Ironwood Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Integrated Wealth Concepts LLC boosted its position in Ironwood Pharmaceuticals by 21.4% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 3,406 shares in the last quarter. Merit Financial Group LLC lifted its holdings in shares of Ironwood Pharmaceuticals by 17.4% during the third quarter. Merit Financial Group LLC now owns 48,879 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 7,232 shares during the period. Rhumbline Advisers raised its holdings in shares of Ironwood Pharmaceuticals by 3.5% during the third quarter. Rhumbline Advisers now owns 223,229 shares of the biotechnology company’s stock worth $292,000 after purchasing an additional 7,611 shares during the last quarter. Focus Partners Wealth boosted its stake in shares of Ironwood Pharmaceuticals by 29.3% in the third quarter. Focus Partners Wealth now owns 44,652 shares of the biotechnology company’s stock worth $58,000 after buying an additional 10,105 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in shares of Ironwood Pharmaceuticals by 83.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 34,331 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 15,594 shares in the last quarter.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.